Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement / Intercell announces Q3 results: Technologies continue to deliver new product candidates - Strong financial situation

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

13.11.2006

Latest Achievements: » EU Grant of EUR 2.3 million for the
development of an otitis media vaccine  » EU Grant of EUR 3.5 million
for the development of a pandemic influenza      vaccine

Technologies continue to create value and prime partnerships »
Strategic alliance with Merck to develop a prophylactic vaccine
against      Group A Streptococcus - USD 85.5 million agreement »
Strategic alliance with Wyeth for the use of Intercell’s IC31TM
adjuvant in      various selected infectious disease vaccines -
payments up to USD 77 million  » Collaboration with PATH for the
development of Intercell’s Streptococcus      pneumoniae vaccine - USD
7.3 m initial funding

Significant progress in product development » Positive results for
Intercell’s Japanese Encephalitis virus vaccine in the      pivotal
Phase III safety trial - Regulatory process towards a Biologics
License Application (BLA) in the United States initiated »
Intercell's therapeutic Hepatitis C T-cell vaccine advances to next
Phase II      clinical trial in chronic Hepatitis C patients using the
optimized route and      frequency of administration  » Intercell
terminates its preclinical collaborative development project for a
therapeutic Hepatitis B vaccine in order to focus its partnership
portfolio

Financials: » Revenues were EUR 6.5 million for the first three
quarters of 2006, compared      to EUR 4.8 million in the same period
of 2005 (up 35.4%) » Primarily due to advancement of JEV vaccine
development, net loss increased      by 21.8% to EUR 21.8 million in
the nine months ended September 30, 2006 from      EUR 17.9 million in
the comparative period of 2005 » Strong cash position of EUR 83.7
million - strong cash-flows from strategic      partnerships expected
in Q4 2006

Vaccine company Intercell AG (VSE: ICLL) today announced its financial results for the third quarter of 2006.

Intercell’s aggregate revenues in the nine months ended September 30, 2006 were EUR 6.5 million, compared to EUR 4.8 million in the same period of 2005. This 35.4 percent increase was due to higher revenues from collaborations and licensing, which increased by 55.6 percent from EUR 3.6 million in the first nine months of 2005 to EUR 5.6 million in the first nine months of 2006. Grant income decreased by 25.0 percent, from EUR 1.2 million in the first three quarters of 2005 to EUR 0.9 million in the first three quarters of 2006.

Intercell’s net loss increased by EUR 3.9 million, or by 21.8 percent, from EUR 17.9 million in the first nine months of 2005 to EUR 21.8 million in the nine months ended September 30, 2006. This increase in net loss was due to an increase in research and development expenses of 24.6 percent and an increase in sales, general and administrative expenses of 18.3 percent. Research and development expenses were EUR 21.8 million in the first three quarters of 2006, compared to EUR 17.5 million in the first three quarters of 2005. This increase was primarily due to increased costs relating to the Phase III clinical trials for Intercell’s JEV vaccine.

Sales general and administrative expenses increased to EUR 7.1 million in the nine months ended September 30, 2006 from EUR 6.0 million in the same period of 2005 and resulted primarily from higher personnel expenses. In aggregate, net operating expenses in the first three quarters of 2006 increased by 18.8 percent to EUR 27.8 million, from EUR 23.4 million in the first nine months of 2005.

Financial Highlights
EUR in thousands                  9 months ended                    Year ended
                            Sept. 30, 2006    Sept. 30, 2005    Dec. 31, 2005
Revenues                            6,483                4,797                8,469
Net loss                         (21,761)          (17,890)          (25,060)
Net operating cash flow (18,059)          (16,166)          (24,023)
Cash and marketable
securities, end of
period                              83,711              59,701              50,178

The full quarterly report including un-audited financial statements can be downloaded at www.intercell.com.

@@start.t2@@end of announcement                                                 euro adhoc 13.11.2006 07:00:31
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: